NR4A1 and cancer: After a median observation period of 4.7 years following pregnancy, there was no difference in time to cancer progression (DFS), regardless of pregnancy or no pregnancy in either the hormone receptor positive group (HR = 0.91; 95% CI, 0.67 to 1.24, p = 0.55) or hormone receptor negative (HR = 0.75; 95% CI, 0.51 to 1.08, p = 0.12) and longer overall survival (OS) in patients who became pregnant (HR = 0.72; 95% CI, 0.54 to 0.97, p = 0.03), regardless of estrogen receptor status (p = 0.11) [64].